All In Biotech

Drug Trial Radar · NCT02322229

Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

May 26, 2015

Primary completion

Dec 11, 2015

Study completion May 9, 2016

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Dec 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.

Conditions

  • Vitreomacular Traction
  • Vitreomacular Adhesion

Interventions

  • Ocriplasmin 0.125 mg in a 0.1 mL volumeDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) EvaluationTime frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Laboratories (Australia) for Trial Locations

    New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.